Currently out of the existing stock ratings of Andrew Galler, 9 are a BUY (45%), 2 are a SELL (10%), 9 are a HOLD (45%).

Andrew Galler

Work Performance Price Targets & Ratings Chart

Analyst Andrew Galler, carries an average stock price target met ratio of 78.13% that have a potential upside of 22.55% achieved within 201 days.

Andrew Galler’s has documented 43 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 06-Oct-2025.

Wall Street Analyst Andrew Galler

Analyst best performing recommendations are on MRNA (MODERNA).
The best stock recommendation documented was for MRNA (MODERNA) at 11/8/2021. The price target of $304 was fulfilled within 18 days with a profit of $59.32 (24.24%) receiving and performance score of 13.47.

Average potential price target upside

of $53.27 (25.02%) on VRTX (VERTEX PHARMACEUTICALS).
of $16.32 (8.22%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $7.52 (31.42%) on VIR (VIR BIOTECHNOLOGY).

FOLD Amicus Therapeutics VIR Vir Biotechnology VRTX Vertex Pharmaceuticals ARWR Arrowhead Pharmaceuticals IMCR Immunocore Holdings Ltd ALNY Alnylam Pharmaceuticals MRNA Moderna PTCT PTC Therapeutics XLRN Acceleron Pharma

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Dennis Ding (JEFFERIES)